ResMed Inc.

160.81-1.00-0.62%Vol 816.17K1Y Perf 40.20%
Jun 4th, 2020 16:00 DELAYED
BID160.82 ASK161.87
Open160.70 Previous Close161.81
Pre-Market161.81 After-Market160.81
 - -%  - -%
Target Price
153.43 
Analyst Rating
Hold 2.67
Potential %
-4.59 
Finscreener Ranking
★+     44.92
Insiders Trans % 3/6/12 mo.
-100/-100/-100 
Value Ranking
★+     46.03
Insiders Value % 3/6/12 mo.
-100/-100/-100 
Growth Ranking
★★★★+     65.34
Insiders Shares Cnt. % 3/6/12 mo.
-100/-100/-100 
Income Ranking
★+     37.92
Market Cap23.26B 
Earnings Rating
Sell
Price Range Ratio 52W %
75.15 
Earnings Date
23rd Jul 2020

Today's Price Range

159.49164.30

52W Range

108.85177.99

5 Year PE Ratio Range

19.1056.30

Summary:

Buy

Technical Indicators: Neutral
Moving Averages: Strong Buy
Performance
1 Week
-0.01%
1 Month
0.88%
3 Months
-5.82%
6 Months
7.08%
1 Year
40.20%
3 Years
121.04%
5 Years
172.44%
10 Years
436.30%

TickerPriceChg.Chg.%
RMD160.81-1.0000-0.62
AAPL322.32-2.8000-0.86
GOOG1 412.18-24.2000-1.68
MSFT182.92-2.4400-1.32
XOM49.10-0.1400-0.28
WFC30.361.53005.31
JNJ146.73-1.9200-1.29
FB226.29-3.8700-1.68
GE7.740.38005.16
JPM106.442.17002.08
Financial StrengthValueIndustryS&P 500US Markets
1.60
2.70
0.39
0.67
15.10
Leverage Ratio 2.00
ProfitabilityValueIndustryS&P 500US Markets
59.30
22.80
29.00
22.50
17.73
RevenueValueIndustryS&P 500US Markets
2.89B
19.99
10.89
11.29
DividendsValueIndustryS&P 500US Markets
0.97
1.56
5.11
6.69
Payout ratio51.00
Earnings HistoryEstimateReportedSurprise %
Q03 20201.001.2929.00
Q02 20201.011.2119.80
Q01 20200.870.936.90
Q04 20190.920.953.26
Q03 20190.840.895.95
Q02 20190.951.005.26
Q01 20190.800.811.25
Q04 20180.900.955.56
Earnings Per EndEstimateRevision %Trend
6/2020 QR0.96-11.93Negative
6/2020 FY4.412.80Positive
9/2020 QR0.88-17.76Negative
6/2021 FY4.43-5.34Negative
Next Report Date23rd Jul 2020
Estimated EPS Next Report0.96
Estimates Count4
EPS Growth Next 5 Years %14.00
Volume Overview
Volume816.17K
Shares Outstanding144.67M
Trades Count12.73K
Dollar Volume181.20M
Avg. Volume730.77K
Avg. Weekly Volume581.25K
Avg. Monthly Volume610.20K
Avg. Quarterly Volume848.98K

ResMed Inc. (NYSE: RMD) stock closed at 160.81 per share at the end of the most recent trading day (a -0.62% change compared to the prior day closing price) with a volume of 819.36K shares and market capitalization of 23.26B. Is a component of S&P 500, Russell 1000 indices and it is traded on NYSE exchange. The company belongs in the Medical Devices & Instruments industry, Healthcare sector and employs 7240 people. ResMed Inc. CEO is Michael J. Farrell.

The one-year performance of ResMed Inc. stock is 40.2%, while year-to-date (YTD) performance is 3.77%. RMD stock has a five-year performance of 172.44%. Its 52-week range is between 108.85 and 177.99, which gives RMD stock a 52-week price range ratio of 75.15%

ResMed Inc. currently has a PE ratio of 45.70, a price-to-book (PB) ratio of 10.31, a price-to-sale (PS) ratio of 8.06, a price to cashflow ratio of 38.10, a PEG ratio of 2.32, a ROA of 11.91%, a ROC of 15.40% and a ROE of 23.97%. The company’s profit margin is 17.73%, its EBITDA margin is 29.00%, and its revenue ttm is $2.89 Billion , which makes it $19.99 revenue per share.

Of the last four earnings reports from ResMed Inc., there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.96 for the next earnings report. ResMed Inc.’s next earnings report date is 23rd Jul 2020.

The consensus rating of Wall Street analysts for ResMed Inc. is Hold (2.67), with a target price of $153.43, which is -4.59% compared to the current price. The earnings rating for ResMed Inc. stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

ResMed Inc. has a dividend yield of 0.97% with a dividend per share of $1.56 and a payout ratio of 51.00%.

ResMed Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 10.53, ATR14 : 5.55, CCI20 : -17.04, Chaikin Money Flow : -0.05, MACD : 0.25, Money Flow Index : 61.90, ROC : -1.08, RSI : 50.48, STOCH (14,3) : 56.86, STOCH RSI : 0.86, UO : 53.10, Williams %R : -43.14), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of ResMed Inc. in the last 12-months were: Brett Sandercock (Sold 32 500 shares of value $4 751 955 ), Carol J. Burt (Sold 10 000 shares of value $1 648 954 ), David B. Pendarvis (Sold 0 shares of value $-2 891 719 ), David B. Pendarvis (Sold 50 267 shares of value $7 371 380 ), David Pendarvis (Sold 0 shares of value $-1 463 011 ), David Pendarvis (Sold 26 202 shares of value $3 453 667 ), James Hollingshead (Sold 0 shares of value $-46 592 ), James Hollingshead (Sold 800 shares of value $98 536 ), James R. Hollingshead (Sold 0 shares of value $-3 093 126 ), James R. Hollingshead (Sold 56 876 shares of value $8 324 062 ), Jim Hollingshead (Sold 0 shares of value $-93 184 ), Jim Hollingshead (Sold 1 600 shares of value $202 136 ), John P. Wareham (Sold 0 shares of value $-1 193 454 ), John P. Wareham (Sold 20 492 shares of value $3 032 967 ), Michael J. Farrell (Sold 0 shares of value $-3 191 840 ), Michael J. Farrell (Sold 74 527 shares of value $10 224 271 ), Rajwant Sodhi (Sold 14 100 shares of value $2 135 369 ), Richard McHale (Sold 18 306 shares of value $2 519 752 ), Robert Andrew Douglas (Sold 0 shares of value $-576 920 ), Robert Andrew Douglas (Sold 25 166 shares of value $3 489 106 ), Robert Douglas (Sold 0 shares of value $-1 009 773 ), Robert Douglas (Sold 32 666 shares of value $4 208 340 ), Ronald R. Taylor (Sold 4 429 shares of value $603 863 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
3 (33.33 %)
2 (22.22 %)
2 (22.22 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
4 (44.44 %)
6 (66.67 %)
6 (66.67 %)
Moderate Sell
1 (11.11 %)
1 (11.11 %)
1 (11.11 %)
Strong Sell
1 (11.11 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingHold
2.67
Hold
2.67
Hold
2.67

ResMed Inc.

ResMed Inc is one of the largest global respiratory medical devices companies, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns 65% of revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payor in the out-of-hospital setting.

CEO: Michael J. Farrell

Teplephone: +1 858 836-5000

Address: 9001 Spectrum Center Boulevard, San Diego 92123, CA, USA

Number of employees: 7 240

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

50%50%

Bearish Bullish

44%56%

Bearish Bullish

54%46%

News

Stocktwits